141 related articles for article (PubMed ID: 38472339)
1. RNA processing modification mediated subtypes illustrate the distinctive features of tumor microenvironment in hepatocellular carcinoma.
Li X; Liu S; Zou L; Dai M; Zhu C
Genes Immun; 2024 Apr; 25(2):132-148. PubMed ID: 38472339
[TBL] [Abstract][Full Text] [Related]
2. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
3. Cuproptosis-associated genes (CAGs) contribute to the prognosis prediction and potential therapeutic targets in hepatocellular carcinoma.
Shi X; Shi D; Yin Y; Wu Y; Chen W; Yu Y; Wang X
Cell Signal; 2024 May; 117():111072. PubMed ID: 38307306
[TBL] [Abstract][Full Text] [Related]
4. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
Huang X; Qiu Z; Li L; Chen B; Huang P
Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607
[TBL] [Abstract][Full Text] [Related]
5. Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma.
Mo Z; Liu D; Rong D; Zhang S
Front Immunol; 2021; 12():611058. PubMed ID: 33679749
[No Abstract] [Full Text] [Related]
6. N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment.
Shi Y; Wang Y; Zhang W; Niu K; Mao X; Feng K; Zhang Y
Front Endocrinol (Lausanne); 2023; 14():1153802. PubMed ID: 37469973
[TBL] [Abstract][Full Text] [Related]
7. Integrated investigation of the clinical implications and targeted landscape for RNA methylation modifications in hepatocellular carcinoma.
Zhang J; Gao J; Hu M; Xu S; Cheng C; Zheng W; Zhang J
Eur J Med Res; 2023 Jan; 28(1):46. PubMed ID: 36707911
[TBL] [Abstract][Full Text] [Related]
8. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
9. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
10. Novel application of the ferroptosis-related genes risk model associated with disulfidptosis in hepatocellular carcinoma prognosis and immune infiltration.
Wei J; Wang J; Chen X; Zhang L; Peng M
PeerJ; 2024; 12():e16819. PubMed ID: 38317842
[TBL] [Abstract][Full Text] [Related]
11. Construction and validation of a novel signature based on epithelial-mesenchymal transition-related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment.
Gao B; Wang Y; Lu S
Funct Integr Genomics; 2022 Dec; 23(1):6. PubMed ID: 36536232
[TBL] [Abstract][Full Text] [Related]
12. Cuproptosis-related molecular patterns and gene (ATP7A) in hepatocellular carcinoma and their relationships with tumor immune microenvironment and clinical features.
Li S; Weng J; Xiao C; Lu J; Cao W; Song F; He Z; Zhang P; Zhu Z; Xu J
Cancer Rep (Hoboken); 2023 Dec; 6(12):e1904. PubMed ID: 37885090
[TBL] [Abstract][Full Text] [Related]
13. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
Liu R; Liu Y; Zhang F; Wei J; Wu L
Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
[TBL] [Abstract][Full Text] [Related]
14. Identification and validation of a tyrosine metabolism-related prognostic prediction model and characterization of the tumor microenvironment infiltration in hepatocellular carcinoma.
Zhou Y; Li X; Long G; Tao Y; Zhou L; Tang J
Front Immunol; 2022; 13():994259. PubMed ID: 36341373
[TBL] [Abstract][Full Text] [Related]
15. Identification of cell senescence molecular subtypes in prediction of the prognosis and immunotherapy of hepatitis B virus-related hepatocellular carcinoma.
Yu X; Chen P; Yi W; Ruan W; Xiong X
Front Immunol; 2022; 13():1029872. PubMed ID: 36275676
[TBL] [Abstract][Full Text] [Related]
16. The cell death-related genes machine learning model for precise therapy and clinical drug selection in hepatocellular carcinoma.
Du M; Qu Y; Qin L; Zheng J; Sun W
J Cell Mol Med; 2024 Apr; 28(7):e18168. PubMed ID: 38494848
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis and validation of SNX7 as a novel biomarker for the diagnosis, prognosis, and prediction of chemotherapy and immunotherapy response in hepatocellular carcinoma.
Chen J; Gao G; Zhang Y; Dai P; Huang Y
BMC Cancer; 2023 Sep; 23(1):899. PubMed ID: 37743471
[TBL] [Abstract][Full Text] [Related]
18. A novel immunogenic cell death-related genes signature for predicting prognosis, immune landscape and immunotherapy effect in hepatocellular carcinoma.
Xu G; Jiang Y; Li Y; Ge J; Xu X; Chen D; Wu J
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16261-16277. PubMed ID: 37698679
[TBL] [Abstract][Full Text] [Related]
19. The identification of N6-methyladenosine-related miRNAs predictive of hepatocellular carcinoma prognosis and immunotherapy efficacy.
Zou R; Liu Y; Qiu S; Lu Y; Chen Y; Yu H; Zhu H; Zhu W; Zhu L; Feng J; Han J
Cancer Biomark; 2023; 38(4):551-566. PubMed ID: 38007640
[TBL] [Abstract][Full Text] [Related]
20. Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma.
Zhang X; Zhuge J; Liu J; Xia Z; Wang H; Gao Q; Jiang H; Qu Y; Fan L; Ma J; Tan C; Luo W; Luo Y
Front Immunol; 2023; 14():1153423. PubMed ID: 37006285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]